Cargando…

Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study

OBJECTIVE: To examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF. METHODS: This population-based cohort study included 2,685 dementia-free participants from the Swedi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mozhu, Fratiglioni, Laura, Johnell, Kristina, Santoni, Giola, Fastbom, Johan, Ljungman, Petter, Marengoni, Alessandra, Qiu, Chengxuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251601/
https://www.ncbi.nlm.nih.gov/pubmed/30305443
http://dx.doi.org/10.1212/WNL.0000000000006456
_version_ 1783373136228515840
author Ding, Mozhu
Fratiglioni, Laura
Johnell, Kristina
Santoni, Giola
Fastbom, Johan
Ljungman, Petter
Marengoni, Alessandra
Qiu, Chengxuan
author_facet Ding, Mozhu
Fratiglioni, Laura
Johnell, Kristina
Santoni, Giola
Fastbom, Johan
Ljungman, Petter
Marengoni, Alessandra
Qiu, Chengxuan
author_sort Ding, Mozhu
collection PubMed
description OBJECTIVE: To examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF. METHODS: This population-based cohort study included 2,685 dementia-free participants from the Swedish National Study on Aging and Care in Kungsholmen, who were regularly examined from 2001–2004 to 2010–2013. AF was ascertained from clinical examination, ECG, and patient registry. Global cognitive function was assessed using the Mini-Mental State Examination. We followed the DSM-IV criteria for the diagnosis of dementia, the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) criteria for vascular dementia, and the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer disease. Data were analyzed using multiple linear mixed-effects and Cox regression models. RESULTS: We identified 243 participants (9.1%) with AF at baseline. During the 9-year follow-up period, 279 participants (11.4%) developed AF and 399 (14.9%) developed dementia. As a time-varying variable, AF was significantly associated with a faster annual Mini-Mental State Examination decline (β coefficient = −0.24, 95% confidence interval [CI]: −0.31 to −0.16) and an increased hazard ratio (HR) of all-cause dementia (HR = 1.40, 95% CI: 1.11–1.77) and vascular and mixed dementia (HR = 1.88, 95% CI: 1.09–3.23), but not Alzheimer disease (HR = 1.33, 95% CI: 0.92–1.94). Among people with either prevalent or incident AF, use of anticoagulant drugs, but not antiplatelet treatment, was associated with a 60% decreased risk of dementia (HR = 0.40, 95% CI: 0.18–0.92). CONCLUSION: AF is associated with a faster global cognitive decline and an increased risk of dementia in older people. Use of anticoagulant drugs may reduce dementia risk in patients with AF.
format Online
Article
Text
id pubmed-6251601
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-62516012018-12-11 Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study Ding, Mozhu Fratiglioni, Laura Johnell, Kristina Santoni, Giola Fastbom, Johan Ljungman, Petter Marengoni, Alessandra Qiu, Chengxuan Neurology Article OBJECTIVE: To examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF. METHODS: This population-based cohort study included 2,685 dementia-free participants from the Swedish National Study on Aging and Care in Kungsholmen, who were regularly examined from 2001–2004 to 2010–2013. AF was ascertained from clinical examination, ECG, and patient registry. Global cognitive function was assessed using the Mini-Mental State Examination. We followed the DSM-IV criteria for the diagnosis of dementia, the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) criteria for vascular dementia, and the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer disease. Data were analyzed using multiple linear mixed-effects and Cox regression models. RESULTS: We identified 243 participants (9.1%) with AF at baseline. During the 9-year follow-up period, 279 participants (11.4%) developed AF and 399 (14.9%) developed dementia. As a time-varying variable, AF was significantly associated with a faster annual Mini-Mental State Examination decline (β coefficient = −0.24, 95% confidence interval [CI]: −0.31 to −0.16) and an increased hazard ratio (HR) of all-cause dementia (HR = 1.40, 95% CI: 1.11–1.77) and vascular and mixed dementia (HR = 1.88, 95% CI: 1.09–3.23), but not Alzheimer disease (HR = 1.33, 95% CI: 0.92–1.94). Among people with either prevalent or incident AF, use of anticoagulant drugs, but not antiplatelet treatment, was associated with a 60% decreased risk of dementia (HR = 0.40, 95% CI: 0.18–0.92). CONCLUSION: AF is associated with a faster global cognitive decline and an increased risk of dementia in older people. Use of anticoagulant drugs may reduce dementia risk in patients with AF. Lippincott Williams & Wilkins 2018-11-06 /pmc/articles/PMC6251601/ /pubmed/30305443 http://dx.doi.org/10.1212/WNL.0000000000006456 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Ding, Mozhu
Fratiglioni, Laura
Johnell, Kristina
Santoni, Giola
Fastbom, Johan
Ljungman, Petter
Marengoni, Alessandra
Qiu, Chengxuan
Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title_full Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title_fullStr Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title_full_unstemmed Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title_short Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study
title_sort atrial fibrillation, antithrombotic treatment, and cognitive aging: a population-based study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251601/
https://www.ncbi.nlm.nih.gov/pubmed/30305443
http://dx.doi.org/10.1212/WNL.0000000000006456
work_keys_str_mv AT dingmozhu atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT fratiglionilaura atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT johnellkristina atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT santonigiola atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT fastbomjohan atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT ljungmanpetter atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT marengonialessandra atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy
AT qiuchengxuan atrialfibrillationantithrombotictreatmentandcognitiveagingapopulationbasedstudy